Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFβ and activin A suppression

  • Rea, Anna|||0000-0003-1307-8045
  • Santana-Hernández, Sara|||0000-0001-7440-8445
  • Villanueva, Javier
  • Sanvicente-García, Marta|||0000-0002-4508-2834
  • Cabo, Mariona
  • Suarez-Olmos, Jesús
  • Quimis, Fabricio
  • Qin, Mengjuan|||0000-0001-7014-7188
  • Llorens, Eduard
  • Blasco-Benito, Sandra
  • Torralba-Raga, Lamberto
  • Perez, Lorena
  • Bhattarai, Bishan
  • Alari Pahissa, Elisenda|||0000-0001-7424-5383
  • Georgoudaki, Anna-Maria
  • Balaguer, Francesc|||0000-0002-0206-0539
  • Juan, Manel|||0000-0002-3064-1648
  • Pardo, Julián|||0000-0003-0154-0730
  • Celià-Terrassa, Toni|||0000-0002-0615-8744
  • Rovira, Ana|||0000-0003-1301-2599
  • Möker, Nina
  • Zhang, Congcong|||0000-0003-3693-4705
  • Colonna, Marco|||0000-0001-5222-4987
  • Spanholtz, Jan|||0000-0001-7152-6956
  • Malmberg, Karl-Johan|||0000-0002-8718-9373
  • Montagut, Clara
  • Albanell Mestres, Joan|||0000-0003-1239-4580
  • Güell, Marc|||0000-0003-4000-7912
  • López-Botet, Miguel|||0000-0003-4882-065X
  • Muntasell i Castellví, Aura|||0000-0003-2894-0486
Transforming growth factor beta (TGFβ) and activin A suppress natural killer (NK) cell function and proliferation, limiting the efficacy of adoptive NK cell therapies. Inspired by the partial resistance to TGFβ of NK cells with SMAD4 haploinsufficiency, we used CRISPR-Cas9 for knockout of SMAD4 in human NK cells. Here we show that SMAD4 NK cells were resistant to TGFβ and activin A inhibition, retaining their cytotoxicity, cytokine secretion and interleukin-2/interleukin-15-driven proliferation. They showed enhanced tumor penetration and tumor growth control, both as monotherapy and in combination with tumor-targeted therapeutic antibodies. Notably, SMAD4 NK cells outperformed control NK cells treated with a TGFβ inhibitor, underscoring the benefit of maintaining SMAD4-independent TGFβ signaling. SMAD4 conferred TGFβ resistance across diverse NK cell platforms, including CD19-CAR NK cells, stem cell-derived NK cells and ADAPT-NK cells. These findings position SMAD4 knockout as a versatile and compelling strategy to enhance NK cell antitumor activity, providing a new avenue for improving NK cell-based cancer immunotherapies.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFβ and activin A suppression

  • Rea, Anna
  • Santana-Hernández, Sara
  • Villanueva, Javier
  • Sanvicente-García, Marta
  • Cabo, Mariona, 1991-
  • Suárez Olmos, Jesús
  • Quimis, Fabricio
  • Qin, Mengjuan
  • Llorens, Eduard
  • Blasco-Benito, Sandra
  • Alari-Pahissa, Elisenda
  • Celià-Terrassa, Toni
  • Montagut Viladot, Clara
  • Albanell Mestres, Joan
  • Güell Cargol, Marc, 1982-
  • López-Botet, M. (Miguel)
  • Muntasell i Castellví, Aura, 1972-
Transforming growth factor beta (TGFβ) and activin A suppress natural killer (NK) cell function and proliferation, limiting the efficacy of adoptive NK cell therapies. Inspired by the partial resistance to TGFβ of NK cells with SMAD4 haploinsufficiency, we used CRISPR-Cas9 for knockout of SMAD4 in human NK cells. Here we show that SMAD4KO NK cells were resistant to TGFβ and activin A inhibition, retaining their cytotoxicity, cytokine secretion and interleukin-2/interleukin-15-driven proliferation. They showed enhanced tumor penetration and tumor growth control, both as monotherapy and in combination with tumor-targeted therapeutic antibodies. Notably, SMAD4KO NK cells outperformed control NK cells treated with a TGFβ inhibitor, underscoring the benefit of maintaining SMAD4-independent TGFβ signaling. SMAD4KO conferred TGFβ resistance across diverse NK cell platforms, including CD19-CAR NK cells, stem cell-derived NK cells and ADAPT-NK cells. These findings position SMAD4 knockout as a versatile and compelling strategy to enhance NK cell antitumor activity, providing a new avenue for improving NK cell-based cancer immunotherapies., This work was supported by grants PI19/00328 and PI22/00040 (to A.M.), ICI24/00041 (to A.M. and C.M.), PI21/00002 (to J.A.) funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, Generalitat de Catalunya SGR863 (to M.L.-B. and A.M.), 2024PROD00086 (to A.M.), EC Horizon 2020 Marie Sklodowska Curie-Innovative Training Network 765104 (to A. Rea, M.L.-B., N.M., K.-J.M. and J.S.), Ministerio de Ciencia, Innovación y Universidades/FEDER CNS2023-144487 (to A.M.), CIBERONC: CB16/12/00241 (to J.A.), PID2020-113963RBI00 (to J.P.), PID2023-147310OB-I00 (to T.C.-T.), Gobierno de Aragón B29-23R (to J.P.), AECC postdoctoral fellowship POSTD234709BLAS (to S.B.-B.), Research Council of Norway 275469 and 237579 (to K.-J.M.), the Research Council of Norway through its Centres of Excellence scheme 332727 (to K.-J.M.), the Norwegian Cancer Society-190386, 223310 (to K.-J.M.), The South-Eastern Norway Regional Health Authority 2021-073 and 2024-053 (to K.-J.M.), Knut and Alice Wallenberg Foundation 2018.0106 (to K.-J.M.), Swedish Foundation for Strategic Research (to K.-J.M.) and the US National Cancer Institute P01 CA111412, P009500901 (to K.-J.M.) and CRIS EXCELLENCE 19–30, funded by CRIS Contra el Cáncer (to C.M.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Integrated analysis of circulating immune cellular and soluble mediators reveals specific COVID19 signatures at hospital admission with utility for prediction of clinical outcomes

  • Uranga Murillo, Iratxe
  • Morte Romea, Elena
  • Hidalgo, Sandra
  • Pesini, Cecilia
  • García-Mulero, Sandra
  • Sierra Monzón, José L.
  • Santiago, Llipsy
  • Arias, Maykel
  • Miguel, Diego de
  • Encabo-Berzosa, M. Mar
  • Gracia Tello, Borja
  • Sanz-Pamplona, Rebeca
  • Martínez-Lostao, Luis
  • Gálvez Buerba, Eva Mª
  • Paño, José Ramón
  • Ramírez-Labrada, Ariel
  • Pardo, Julián
6 figures, 6 tables.-- This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions., Coronavirus disease 2019 (COVID19), caused by SARS-CoV-2, is a complex disease, with a variety of clinical manifestations ranging from asymptomatic infection or mild cold-like symptoms to more severe cases requiring hospitalization and critical care. The most severe presentations seem to be related with a delayed, deregulated immune response leading to exacerbated inflammation and organ damage with close similarities to sepsis., [Methods]: In order to improve the understanding on the relation between host immune response and disease course, we have studied the differences in the cellular (monocytes, CD8+ T and NK cells) and soluble (cytokines, chemokines and immunoregulatory ligands) immune response in blood between Healthy Donors (HD), COVID19 and a group of patients with non-COVID19 respiratory tract infections (NON-COV-RTI). In addition, the immune response profile has been analyzed in COVID19 patients according to disease severity., [Results]: In comparison to HDs and patients with NON-COV-RTI, COVID19 patients show a heterogeneous immune response with the presence of both activated and exhausted CD8+ T and NK cells characterised by the expression of the immune checkpoint LAG3 and the presence of the adaptive NK cell subset. An increased frequency of adaptive NK cells and a reduction of NK cells expressing the activating receptors NKp30 and NKp46 correlated with disease severity. Although both activated and exhausted NK cells expressing LAG3 were increased in moderate/severe cases, unsupervised cell clustering analyses revealed a more complex scenario with single NK cells expressing more than one immune checkpoint (PD1, TIM3 and/or LAG3). A general increased level of inflammatory cytokines and chemokines was found in COVID19 patients, some of which like IL18, IL1RA, IL36B and IL31, IL2, IFNα and TNFα, CXCL10, CCL2 and CCL8 were able to differentiate between COVID19 and NON-COV-RTI and correlated with bad prognosis (IL2, TNFα, IL1RA, CCL2, CXCL10 and CXCL9). Notably, we found that soluble NKG2D ligands from the MIC and ULBPs families were increased in COVID19 compared to NON-COV-RTI and correlated with disease severity., [Conclusions]: Our results provide a detailed comprehensive analysis of the presence of activated and exhausted CD8+T, NK and monocyte cell subsets as well as extracellular inflammatory factors beyond cytokines/chemokines, specifically associated to COVID19. Importantly, multivariate analysis including clinical, demographical and immunological experimental variables have allowed us to reveal specific immune signatures to i) differentiate COVID19 from other infections and ii) predict disease severity and the risk of death., The authors would like to thank the Biobank of the Aragon Health System integrated in the Spanish National Biobanks Network and the Servicios Científico Técnicos de Citometria de Flujo del CIBA for their collaboration. Work in the JP laboratory is funded by the FEDER (Fondo Europeo de Desarrollo Regional, Gobierno de Aragón, Group B29_17R), Health National Institute Carlos III (COV20-00308), Aragón Government (Fondo COVID-19), Fundación Santander-Universidad de Zaragoza (Programa COVID-19), Agencia Estatal de Investigación (SAF2017-83120-C2-1-R; PID2020-113963RBI00), Fundación Inocente, ASPANOA and Carrera de la Mujer de Monzón. EMG is funded by Agencia Estatal de Investigación (SAF2017-83120-C2-1-R and PID2020-113963RB-I00). IUM and SH are supported by a PhD fellowship from Aragon Government, CP by a PhD fellowship from AECC, LS by a PhD fellowship (FPI) from the Ministry of Science, Innovation and Universities. DDM is supported by a postdoctoral fellowship 'Sara Borrell', and MA is supported by a postdoctoral fellowship 'Juan de la Cierva-incorporacion' from the Ministry of Science, Innovation and Universities. EM and BGT are supported by Rio Hortega contract. JP is supported by the ARAID Foundation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Datos de investigación Set de datos (Dataset)

Supplementary material for Integrated analysis of circulating immune cellular and soluble mediators reveals specific COVID19 signatures at hospital admission with utility for prediction of clinical outcomes [Dataset]

  • Uranga Murillo, Iratxe
  • Morte Romea, Elena
  • Hidalgo, Sandra
  • Pesini, Cecilia
  • García-Mulero, Sandra
  • Sierra Monzón, José L.
  • Santiago, Llipsy
  • Arias, Maykel
  • Miguel, Diego de
  • Encabo-Berzosa, M. Mar
  • Gracia Tello, Borja
  • Sanz-Pamplona, Rebeca
  • Martínez-Lostao, Luis
  • Gálvez Buerba, Eva Mª
  • Paño, José Ramón
  • Ramírez-Labrada, Ariel
  • Pardo, Julián
Sample processing: Peripheral blood was collected into sodium heparin tubes and centrifuged for 10 min at 8 2500 rpm at room temperature (RT) to separate the cellular fraction from the plasma. The plasma was removed from the cell pellet and stored at -80 ºC for posterior use. The cell pellet was diluted 1:1 in RPMI 1640 medium and carefully added to Histopaque-1077 (Sigma) for peripheral blood mononuclear cell (PBMC) isolation by centrifugation at 2500 rpm at RT for 10 min. PBMC layer was collected, washed with RPMI 1640, counted and aliquoted for staining and flow cytometry analysis. All flow cytometry analyses were performed using fresh PBMCs. Flow cytometry: For the surface staining, PMBCs were resuspended in 50 μl PBS with 5 % FCS and stained with the different antibody cocktails for 20 min at 4 ºC in dark, washed twice with PBS + 5 % FCS and then fixed for 30 min at 4 ºC in the dark using 2% PFA. Following surface staining, cells that required intracellular staining were fixed/permeabilized for 30 min at 4 ºC in the dark using the FoxP3 transcription factor buffer kit (Miltenyi). Following fixation/permeabilization, cells were washed twice with permeabilization buffer, resuspended in 50 μl permeabilization buffer and stained with intracellular antibodies for 30 min at 4 ºC in the dark. Samples were washed twice with permeabilization buffer following staining and fixed. All samples were acquired on a Gallios (Beckman Coulter) Flow Cytometer. The list of the antibodies used for immune cell phenotyping was: Miltenyi Biotec, CD14-VioBlue (130-110-524), CD16-FITC (130-25 113-392), CD25-APC (130-113-280), CD3-VioGreen (130-113-134), CD38-FITC (130-113-426), Treg detection kit CD4/CD25/CD127 (130-096-082), CD56-PerCP Vio700 (130-100-681), CD57-27 APC-Vio770 (130-111-813), CD8-PerCP Vio700 (130-110-682), FoxP3 Staining Buffer Set(130-28 093-142), GzmB-PE (130-116-486), HLADR-APC-VIO770 (130-111-792), LAG3-APC (130-105-29 453), NKG2A-PE-VIO615 (130-120-035), NKG2C-PE (130-103-635), NKP46-APC (130-092-609), TIM3-PE vio770 (130-121-334); Biolegend, NKp30-PE/Cy7 (325214), PD1-Alexa Fluor700 31 (329952), CD45-Brilliant Violet 421 (304032); BD, NKG2D-BV421 (743558). High dimensional flow cytometry data analysis: viSNE and FlowSOM (Self-organizing map) analyses were performed using Cytobank (https://cytobank.org). We used t-distributed stochastic neighbouring embedding (t-SNE) to reduce the dimensionality of the cell marker datasets generated using the antibody panels indicated above. FlowSOM clustering analysis compared expression of cell markers was used to identify each cluster and perform an unbiased analysis of the PBMC immunophenotyping data. CD56+ cells, CD56+ or CD14+ cells and CD3+CD8+ cells from FACS panels 2, 3 and 4 respectively, were analysed separately. SOM was generated using equal sampling of at least 1000 cells from each FCS file and hierarchical consensus clustering by the following markers: CD3, CD16, CD57, NKp30, NKp46, NKG2C, NKG2D and NKG2A for panel 2 analysis; CD14, CD3, HLA-DR, CD16, GZMB, TIM3, LAG3, PD1 or CD56,CD3, HLA-DR, CD16, GZMB, TIM3, LAG3, PD1 for panel 3 analysis and GzmB, CD38, HLA-DR, TIM3, LAG3, PD1 for panel 3 analysis. For each SOM, 100 clusters and 5, 8 or 10 metaclusters (MTs) were identified for panel 2, panel 3 and 4, which were represented in Minimum Spanning Trees (MTS). Multiplex plasma protein analyses: Luminex assay was run according to manufacturer’s instructions in 100 μl of plasma, using a custom human cytokine panel (RD Systems, catalogue no. LXSAHM). The next proteins were included: IFNα, IFNβ, IFN, IL28A/IFNλ2, IL28B/IFNλ3, IL2, IL1β,IL18/IL1F4,IL1RA,IL33, IL36b/IL1F8, IL7, IL10, IL31, IL6, IL12/IL23 p40, IL15, IL17E/IL25, IL8/CXCL8, CXCL10/IP10, CCL2/MCP1, CCL8/MCP2, CXCL9/MIG, CXCL2/MIP2α, MICA, MICB, ULBP-1, ULBP-2/5/6, ULBP-52 3, TNFα, GzmA and GzmB. Supernatants were mixed with beads coated with capture antibodies and incubated on a 96 well filter plate for 2 hours. Beads were washed and incubated with biotin-labelled detection antibodies for 1 hour, followed by a final incubation with streptavidin-PE. Assay plates were measured using a Luminex 200 instrument (ThermoFisher, catalogue no. APX10031). Data acquisition and analysis were performed using xPONENT software. The standard curve for each analyte had a five-parameter R2 value > 0.95 with or without minor fitting using xPONENT software. Granzyme activity assay in serum: Serum samples were used to evaluate the activity of both GzmA and GzmB using specific quenching FRET fluorescent substrates (FAM-VANRSAS-DABCYL and FAM-IEPDNLV-DABCYL peptides, respectively). In a nutshell, 40 μl of 100 mM Tris-HCl pH 8.5 or 100 mM Tris-HCl 50 mM NaCl pH 7.8 (buffers for GzmA or GzmB respectively) were added to flat bottom, black plates, with 10 μl of the serum samples. 50 μl of GzmA or GzmB substrates were added and the fluorescence of the plate was read at time zero and 1 h for GzmA and 24 h for GzmB using 475 nm excitation and 520 nm emission wavelenghts. Gzm activity was calculated based on a calibration curve with known concentrations of carboxyfluorescein. Statistics: To minimize inter-experimental variability and batch effects between patients, all PBMC samples were acquired, processed, and freshly analysed during four consecutive weeks from April to June 2020. Serum and plasma samples were frozen at -80ºC and later on all of them were thawed and analysed at the same time. Univariate and multivariate logistic regression models were developed using two different groups of variables, representing soluble and immunomodulatory factors (Group 1) or cell populations (Group 2) shown in Table S5. Age, sex and lymphocyte counts were included in all groups except for the comparison between HD and COVID19, since these variables were not known in HDs. First, a univariate logistic regression analysis was performed in the corresponding groups. Variables included in the multivariate discriminant analysis were those with a value of p < 0.1 in the univariate logistic regression analysis and / or with a value of p < 0.1 in the medians comparison tests. The univariate statistic test used has been chi-square or Fisher exact test for qualitative variant comparison and Mann-Whitney (comparison of two groups of variables) or Kruskal-Wallis (comparison of more than two groups of variables) for quantitative variant comparison. The post-test used was Benjamini, Krieger and Yekutieli test. Variable normality has been analysed with Kolmogorov-Smirnov test and Rho’s Spearman has been calculated as correlation coefficients. Statistical models were developed to predict COVID19 of diagnostic and severity. A multivariate logistic regression and discriminant analyses were performed to develop predictive models. Area Under the Curve (AUC), OR and CI95% values were reported for significant variables. Nagelkerke R2 was calculated to analyse sample variability and Hosmer-Lemeshow test was performed to analyse goodness of fit for the logistic regression model. Hosmer-Lemeshow p values higher than 0.05 indicate an adequate calibration of the predictive model. The statistics software used was GraphPad Software 7.0, (Inc. San Diego, CA) and SPSS 26.0 (IBM Corp., Armonk, NY).-- This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions., Supplementary materials and methods: sample processing, flow cytometry, high dimensional flow cytometry data analysis, multiplex plasma protein analyses, granzyme activity assay in serum, statistics. Supplementary figure legends (1-5). Supplementary table legends (1-7)., The authors would like to thank the Biobank of the Aragon Health System integrated in the Spanish National Biobanks Network and the Servicios Científico Técnicos de Citometria de Flujo del CIBA for their collaboration. Work in the JP laboratory is funded by the FEDER (Fondo Europeo de Desarrollo Regional, Gobierno de Aragón, Group B29_17R), Health National Institute Carlos III (COV20-00308), Aragón Government (Fondo COVID-19), Fundación Santander-Universidad de Zaragoza (Programa COVID-19), Agencia Estatal de Investigación (SAF2017-83120-C2-1-R; PID2020-113963RBI00), Fundación Inocente, ASPANOA and Carrera de la Mujer de Monzón. EMG is funded by Agencia Estatal de Investigación (SAF2017-83120-C2-1-R and PID2020-113963RB-I00). IUM and SH are supported by a PhD fellowship from Aragon Government, CP by a PhD fellowship from AECC, LS by a PhD fellowship (FPI) from the Ministry of Science, Innovation and Universities. DDM is supported by a postdoctoral fellowship 'Sara Borrell', and MA is supported by a postdoctoral fellowship 'Juan de la Cierva-incorporacion' from the Ministry of Science, Innovation and Universities. EM and BGT are supported by Rio Hortega contract. JP is supported by the ARAID Foundation., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFβ and activin A suppression

  • Rea, Anna
  • Santana-Hernández, Sara
  • Villanueva, Javier
  • Sanvicente-García, Marta
  • Cabo, Mariona, 1991-
  • Suárez Olmos, Jesús
  • Quimis, Fabricio
  • Qin, Mengjuan
  • Llorens, Eduard
  • Blasco-Benito, Sandra
  • Alari-Pahissa, Elisenda
  • Celià-Terrassa, Toni
  • Montagut Viladot, Clara
  • Albanell Mestres, Joan
  • Güell Cargol, Marc, 1982-
  • López-Botet, M. (Miguel)
  • Muntasell i Castellví, Aura, 1972-
Transforming growth factor beta (TGFβ) and activin A suppress natural killer (NK) cell function and proliferation, limiting the efficacy of adoptive NK cell therapies. Inspired by the partial resistance to TGFβ of NK cells with SMAD4 haploinsufficiency, we used CRISPR-Cas9 for knockout of SMAD4 in human NK cells. Here we show that SMAD4KO NK cells were resistant to TGFβ and activin A inhibition, retaining their cytotoxicity, cytokine secretion and interleukin-2/interleukin-15-driven proliferation. They showed enhanced tumor penetration and tumor growth control, both as monotherapy and in combination with tumor-targeted therapeutic antibodies. Notably, SMAD4KO NK cells outperformed control NK cells treated with a TGFβ inhibitor, underscoring the benefit of maintaining SMAD4-independent TGFβ signaling. SMAD4KO conferred TGFβ resistance across diverse NK cell platforms, including CD19-CAR NK cells, stem cell-derived NK cells and ADAPT-NK cells. These findings position SMAD4 knockout as a versatile and compelling strategy to enhance NK cell antitumor activity, providing a new avenue for improving NK cell-based cancer immunotherapies., This work was supported by grants PI19/00328 and PI22/00040 (to A.M.), ICI24/00041 (to A.M. and C.M.), PI21/00002 (to J.A.) funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, Generalitat de Catalunya SGR863 (to M.L.-B. and A.M.), 2024PROD00086 (to A.M.), EC Horizon 2020 Marie Sklodowska Curie-Innovative Training Network 765104 (to A. Rea, M.L.-B., N.M., K.-J.M. and J.S.), Ministerio de Ciencia, Innovación y Universidades/FEDER CNS2023-144487 (to A.M.), CIBERONC: CB16/12/00241 (to J.A.), PID2020-113963RBI00 (to J.P.), PID2023-147310OB-I00 (to T.C.-T.), Gobierno de Aragón B29-23R (to J.P.), AECC postdoctoral fellowship POSTD234709BLAS (to S.B.-B.), Research Council of Norway 275469 and 237579 (to K.-J.M.), the Research Council of Norway through its Centres of Excellence scheme 332727 (to K.-J.M.), the Norwegian Cancer Society-190386, 223310 (to K.-J.M.), The South-Eastern Norway Regional Health Authority 2021-073 and 2024-053 (to K.-J.M.), Knut and Alice Wallenberg Foundation 2018.0106 (to K.-J.M.), Swedish Foundation for Strategic Research (to K.-J.M.) and the US National Cancer Institute P01 CA111412, P009500901 (to K.-J.M.) and CRIS EXCELLENCE 19–30, funded by CRIS Contra el Cáncer (to C.M.).